Bisgaier Charles PhD

Chair & Chief Scientific Off., Director, 10% OwnerGemphire Therapeutics Inc. (GEMP) · full profile →Form 4 · filed Aug 12, 2016
Net Buying
Open-Market Buys
$518K
Open-Market Sells
$0
Net Open-Market Flow
$518K
Transactions
8
5 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 10, 2016Conversion(C)19K$6.71$129K19K
Aug 10, 2016Other(J)7K$6.71$44K66K
Aug 10, 2016Conversion(C)16K$6.71$108K82K
Aug 10, 2016Conversion(C)60K60K
Aug 10, 2016Buy(P)52K$10.00$518K1.2M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 10, 2016Conversion(C)60K$00
Aug 10, 2016Conversion(C)0$00
Aug 10, 2016Conversion(C)0$00

Transaction Codes

C
Conversion of a derivative
J
Other acquisition / disposition
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-16-139254) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Ask your agent about GEMP insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001104659-16-139254"
Ask your agent
Use Arkolith to summarize insider buying and selling at Gemphire Therapeutics Inc.
over the last 90 days and cite the filings.